A rejection of the authorized shares would decimate Lombardo’s negotiation leverage, whether to license or to sell the whole company. But the chances of it happening are close to zero. Institutional investors are well aware that a young biotech absolutely must have the flexibility that a big shares cushion provides.
News 
Market Data 
Discover 
